univers coverag
calendar event
medacorp event post-op pain investor dinner discuss kol
pacira exparel heron new york
medic meet breast surgeri bodi contour symposium intern societi
thrombosi haemostasi societi studi ingest behavior
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
wild ride ahead aaic data could drive
averag dcf price-to-earnings p/sale
bottom line stock face tremend volatil around present
data next week alzheim associ intern confer aaic meet
complet scenario analysi suggest margin result cognit declin
benefit could see stock fall rang posit data benefit
signific dose durat secondari endpoint effect could offer upsid
follow press releas disclos posit result final analysi phase ii
studi month reaction stock
complet scenario analys pinpoint investor current assumpt valu
aducanumab given current price stock
overal hesit recommend stock ahead upcom data present aaic
earli look suggest trelegi royalti worth least upsid
use dr tgr
bottom line therav ownership royalti gsk trelegi ellipta close tripl inhal
laba/lama/ becom signific driver compani stock price recent
decis partner discontinu wholly-own pipelin asset narrow potenti valu
driver compani given observ examin trelegi us prescript data
context respiratori class believ launch trajectori suggest floor valuat
trelegi royalti also believ unreason valu
increas next year launch perform remain durabl
label expans asthma success valu increas would depend either trelegi revenu
expect increas and/or discount rate risk royalti decreas therav
trelegi royalti ownership could also sold futur sourc non-dilut financ addit
pipelin product matur warrant larg late-stag trial would welcom option
investor compani alreadi carri signific convert debt overhang would expect
partial full royalti sale transact occur revenu potenti product clear
like on-going captain trial asthma read earli
european launch asthma label expans could provid futur growth
bottom line yesterday bloomberg report activist may look get involv
ci op -esrx mp deal drive share higher close intra-day close higher
seen relev potenti bid ci implic sharehold vote
aug op also close higher expect rebound sell-off
though possibl specul buy well separ also
view potenti interest medicaid heavi name particular given busi mix
align medicaid elig obamacar shop behavior express strong view
may potenti abl enter deepen presenc drug suppli chain
technolog compani could seiz role digit front healthcar
consum would abl compet sophist mco op
increasingli op integr care deliveri coverag absent substanti acquisit
cross sell prescript drug benefit increas front store sale
foot traffic could facilit deal see ci deep valu name
patient investor combin esrx though expect sharehold vote aug
import binari event stock like trade success view remain
strong buy opportun mp rate though posit bia fundament upsid
take-out
ci close higher report bloomberg activist like get involv ci-esrx deal
potenti impact success sharehold vote schedul aug
also close higher least part rebound sell-off expect
specul buy well possibl take
separ also hear wmt potenti interest medicaid compani
follow lack deal call last fall/wint report wsj
march
also busi mix align wcg
report bloomberg juli hire former execut recent
way sharecar head well view may signal interest
deepen healthcar footprint
pleas see call disrupt
pleas see call amzn partnership xealth
bottom line op report wsj one parti explor acquisit
op conif busi seen sold commun
activ sale talk conif revenu cycl manag busi ebitda
number strateg financi buyer
surpris written potenti interest oper revenu cycl
manag busi broader suit servic hospit system within optum
arm recent purchas advisori board compani give access c-
deal price consist publish view ev ebitda multipl would
offer ev net nci asset
pleas link wsj articl
pleas see link recent tenet call
fda initi biosimilar uptak encourag increment near
bottom line view fda commission scott gottlieb comment brook
institut fda biosimilar action bap releas today link consist
fda previou goal increas avail biosimilar dr gottlieb emphas need
ensur econom viabil biosimilar develop support manufactur interest space
believ worthi concern seen compani like momenta reassess prioriti
biosimilar program given market format slower expect although
hear specif immedi game chang direct fda spur biosimilar competit
believ fda finger puls issu biosimilar today laid sever
initi action plan step forward help bring biosimilar market faster
less up-front invest look specif action fda announc near
four key area focu bap believ fda target right issu look forward
see fda push initi
biosimilar uptak impact commerci intellectu properti hurdl
interchang unlik solv key challeng commerci success biosimilar dr
addit takeaway brook discuss includ
bottom line herein preview our/street expect commercial-stag compani
coverag univers expect pt demand expand payor coverag continu support
exon skip-amen duchenn muscular dystrophy/dmd growth sarepta op
entri new market could translat posit upsid amicu op wherea
believ strength biomarin opcommerci busi remain intact unpredict
order pattern ex-u brazil could emerg x-factor cautiou side script trend
suggest continu volatil ocaliva primari biliari cholangitis/pbc resumpt growth
like materi time compani recent approv drug mp
op earli read patient identif commerci adopt logist consider
includ payor coverag inform determin growth trajectori near- long-
term import coverag smid cap compani howev updat catalyst
-- regulatori clinic relev upcom catalyst hope gain addit insight
includ olorinab data pain associ crohn diseas op file strategi
casimersen exon skip-amen dmd among other compani intend host
analyst day could also make announc eg
sale growth momentum pois continu
ep estim
bottom line share trade today compani deliv anoth solid quarter --
organ top-lin growth admittedli easier comp though still strongest sale growth quarter
recent memori -- fundament remain strong new product growth momentum continu build
manag rais sale guidanc previous indic
organ growth back half year us suggest growth momentum sustain
view print encourag number potenti driver above-market growth
outlook ramp adopt freestyl libr expect instal base reach
total -- intern -- end
today respect estim instal base ou
end solid uptick nutrit consecut quarter growth acceler
sale growth solidli mid-single-digit rang least suggest busi could
sustain healthi low- mid-single-digit growth go forward growth slow area
includ neuromodul cardiac rhythm manag note much
company-specif tie primarili too-slow sale forc build neuro replac headwind
tough compar us much execut stori compani integr
two recent major acquisit stj alr drive new product cycl
medic devic busi steadi turnaround nutrit busi quarter
perform seem posit datapoint support view success
execut valuat rel now-high expect keep us sidelin
acknowledg fundament seem improv
revenu mm ep includ stock compens expens exclud amort
clearli rain gone strong buy
base price-to-earnings ep
bottom line see sell-off post strong buy opportun reiter
outperform rate pt repres upsid current trade level
pt base price-to-earnings revis modestli revis ep convict
base three driver quarter decent bp miss ep
hardli justifi sell-off view everyth amazon- view
disrupt american healthcar potenti make dent retail rx deliveri
even seiz role digit health serious doubt could enter fragment integr
healthcar deliveri system without disrupt transform pipe dream attract
valu view forward price-to-earnings cfo make investor saliv
given revenu growth oper earn growth ep growth profil
dividend pay-out yield also see read-across consumpt pattern reserv
develop mco limit pressur appear relat strong first year
medicar advantag enrol without establish histori risk adjust even growth
op rel tepid year
revenu billion ep dilut show ep exclud non-cash
amort year quarterli number may sum full-year number due round
takeaway novarti earn commentari
bottom line provid quick takeaway gener coverag univers
follow novarti earn call morn sandoz gener divis
takeaway impact coverag univers includ downward revis sandoz
guidanc due meaning chang price eros expect sandoz gener
advair launch expect reiter glatopa impact greater-than-
expect price pressur driver lower guidanc
tcr safeti updat increment posit efficaci updat
bottom line morn adap announc favor safeti review one billion cell dose
cohort cell receptor tcr non-smal cell lung cancer nsclc studi safeti
review committe endors dose escal third dose cohort mage-
tcr studi nsclc tripl tumor view updat increment derisk adap
tcr platform given lack off-target bind alloreact observ high dose
potenti cross-react linger concern investor kol address controversi ahead
multipl data readout adap clinic stage biotechnolog compani pioneer
develop t-cell base immunotherapi cancer adap tcr platform could potenti
address solid tumor view transform cell therapi space success adap
proprietari platform enabl gener engin tcr-base cell therapi permit target
wide rang antigen exploit monoclon antibodi chimer antigen
receptor -t view adap leader potenti disrupt tcr field howev
also view execut key adap stori natur consequ adap leadership posit
rel new tcr field develop risk includ time clinic progress due hurdl
associ enrol screen patient involv physician educ discoveri true
rate antigen express clinic vs publish literatur well human leukocyt antigen hla
restrict view potenti import valid year adap tcr platform multipl
data readout expect includ adap proprietari clinic stage tcr program
afp repres key valu driver compani
momentum continu consum dna test becom top seller
bottom line report morn prime day event dna test
prove one top seller test heavili discount prime day
seen thanksgiv break winter holiday discount drive signific
volum genet test uptak microarray report test among
top seller exclud devic though exact number kit
sold two top seller sold instant pot qt multi use unit
lifestraw person filter note bode well microarray busi
expect consum genom momentum continu year microarray account
revenu repres growth y/i recal consum
genom market experienc inflexion point million sampl genotyp sequenc
platform volum previou year combin
fasinumab valu recoveri possibl pfizer result
bottom line morn lilli announc long-anticip first pivot trial result
ngf antibodi tanezumab treatment osteoarthr pain tanezumab
first ngf antibodi advanc pivot trial import earli indic class
direct valuat spillov outlook regeneron regeneron ngf antibodi
fasinumab phase trial partner teva result first phase
trial import gener discount catalyst regeneron stock later year
execut still new rep hire remain track pt
 methodolog combin sale dcf analysi wacc lt
bone pick medacorp survey suggest solid crysvita adopt esp
ped
 methodolog dcf analysi discount rate termin growth
gene therapi program glycogen storag diseas could sweeten
analysi discount rate termin growth
ftc grant anti-trust clearanc verscend/verita acquisit
risk/reward increasingli attract execut still pt
 methodolog ev/sal multipl sale estim
strong highlight new product momentum major categori
preview pocket opportun
clean safeti encourag expect efficaci readout
valuat use discount rate lt growth rate
earn read-through pharmaci suppli chain
strong oper growth momentum sustain
ep
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
aug omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom aug
potenti approv oct time-frame could move stock meaning
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
mid-august hire extern sale rep cologuard screen
cologuard highli under-penetr strong popul need
colorect cancer screen believ could deliv penetr
revenu longer term penetr ttm sale
recent analysi util leerink healthcar advanc analyt suggest
hire extern rep remain track complet mid-august earlier
timelin highlight
view revenu growth depend fast compani hire sale rep
particularli extern rep harder find hire intern one
turn drive new physician reorder catalyz growth exist physician order
rep hire faster abl reach new pcp aggress
abl serv exist account sooner and/or frequent -- ultim drive upsid
estim take month rep becom fulli product
result updat like late juli
augment trial approach complet top-lin result releas
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac ew
fda adcom joint meet drug safeti risk manag anesthet
fda adcom antimicrobi drug omadacyclin acut bacteri skin skin
structur infect absssi community-acquir bacteri pneumonia cabp
medcac panel t-cell therapi
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
societi studi ingest behavior
intern societi thrombosi haemostasi
breast surgeri bodi contour symposium
american societi retina specialist
societi neurointervent surgeri
american associ physicist medicin
american associ clinic chemistri
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
go live az
model recent updat pleas contact
leerink repres wish review model
biopharma preview gener pain women anti-infect
hcit distribut preview pocket opportun
medic suppli devic individu co preview cardio large-cap
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
-- flash aducanumab phase trial expand variabl endpt requir
 growth margin management stabil still lack pipelin catalyst market
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
deal capac
 come-back stori make survey support opu market
share assumpt outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
